Global Dry Eye Disease Market Size, Share, Growth Analysis, By Product, By Distribution Channel - Industry Forecast 2022-2028 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Dry Eye Disease Market Size, Share, Growth Analysis, By Product, By Distribution Channel - Industry Forecast 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Global dry eye disease market size was valued at US$ 5.95 billion in 2021, and it is expected to reach a value of US$ 8.21 billion by 2028, at a CAGR of more than 4.71% over the forecast period (2022- 2028).

Segments covered in this report

The global dry eye disease market is segmented based on the product, distribution channel and region. Based on the product, it is segmented into artificial tears, anti-inflammatory drugs, punctal plugs, secretagogues, and others. Based on distribution channel, it is segmented into hospital pharmacies, independent pharmacies & drug stores, and online pharmacies. Based on region it is categorized into North America, Europe, Asia-Pacific, Latin America, and MEA.

Driver

The market in dry eye disease is driven by the disease's growing prevalence. The amount of people that have dry eye disease is expected to rise due to an ageing population, increased computer and smartphone use, as well as other reasons. The creation of new treatment options and rising disease awareness are also contributing to the market's growth. The market is also being driven by the healthcare industry's increasing use of telemedicine and digital therapeutics.

Restraint

The high cost of treatment is the dry eye disease market. Some patients lack access to the expensive treatment options for dry eye disease. Another barrier to the market's potential expansion is the absence of potent treatments for severe dry eye disease. In addition, the lengthy and expensive regulatory approval procedure for novel treatments might serve as a barrier to the market's continued growth.

Market Trends

The market for dry eye illness is also where personalised medicine is becoming more and more relevant. Recent advancements are making it easier to identify the root causes of dry eye disease, opening the door to more specialised and customized treatment choices.

Another trend is the increasing use of artificial intelligence (AI) and machine learning in the analysis and management of dry eye disease. AI can assist in finding patterns in patient data to produce more accurate diagnoses and treatment recommendations. The demand for less costly, riskier, and the all solutions for dry eye disease is yet another factor driving market expansion.

A selection of companies mentioned in this report includes

• ALLERGAN (Ireland)
• Alcon (Switzerland)
• Novartis AG (Switzerland)
• Santen Pharmaceutical Co., Ltd. (Japan)
• OASIS Medical (US)
• Sun Pharmaceutical Industries Ltd (India)
• Otsuka Pharmaceutical Co., Ltd. (Japan)
• Sentiss Pharma Pvt. Ltd. (India)
• Johnson & Johnson Vision Care, Inc. (US)
• VISUfarma (Netherlands)

For more information about this report visit https://www.researchandmarkets.com/r/l1n802

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.